Overview
IMRX market data
Price History
IMRX price chart
Valuation & Profitability
No Valuation Data Yet
Alpha Vantage and Twelve Data both returned no valuation metrics for IMRX. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.
Company news
Immuneering Publishes New Findings In Cancer Research Characterizing The Differentiated Mechanism And Broad Preclinical Activity Of Atebimetinib; Atebimetinib Showed Broad Antitumor Activity Across KRAS-, NRAS-, And BRAF-mutant Models, Including Colorectal, Lung, And Melanoma, By Resisting The RAF-Mediated Bypass Signaling That Has Constrained Other MEK InhibitorsBenzinga · Jul 21, 2026, 8:13 PM
Needham Maintains Buy on Immuneering, Raises Price Target to $18Benzinga · Jul 20, 2026, 10:33 AM
Cantor Fitzgerald Initiates Coverage On Immuneering with Overweight RatingBenzinga · Jul 8, 2026, 1:15 PM
8-K filing — Immuneering Corp (IMRX)SEC EDGAR · Jun 15, 2026, 8:12 PM
Immuneering Appoints Andrew Gengos CFO, Effective July 16Benzinga · Jun 15, 2026, 11:40 AM
Immuneering Doses First Patient In MAPKeeper 301 Pivotal Phase 3 Clinical Study Of Atebimetinib Plus Modified Gemcitabine/Nab-Paclitaxel To Treat Metastatic Pancreatic Cancer PatientsBenzinga · Jun 11, 2026, 11:33 AM
Immuneering shares are trading lower. The company announced updated clinical data from its ongoing Phase 2a trial evaluating atebimetinib in combination with modified gemcitabine/nab-paclitaxel in first-line metastatic pancreatic ductal adenocarcinoma.Benzinga · Jun 1, 2026, 3:16 PM
Immuneering Announces Updated Clinical Data From Ongoing Phase 2a Trial Evaluating Atebimetinib In Combination With mGnP In First-Line Metastatic Pancreatic Ductal AdenocarcinomaBenzinga · Jun 1, 2026, 11:36 AM
Crude Oil Edges Higher; US Consumer Sentiment Falls In MayBenzinga · May 22, 2026, 5:05 PM
Zoom Upbeat Q1 Results, Joins Lionsgate Studios, Ross Stores And Other Big Stocks Moving Higher On FridayBenzinga · May 22, 2026, 2:05 PM